Published in Virus Res on September 01, 1998
A dual infection/competition assay shows a correlation between ex vivo human immunodeficiency virus type 1 fitness and disease progression. J Virol (2000) 2.68
Mechanisms involved in stimulation of human immunodeficiency virus type 1 replication by aminooxypentane RANTES. J Virol (2001) 1.12
Extensive purifying selection acting on synonymous sites in HIV-1 Group M sequences. Virol J (2008) 0.94
A human immunodeficiency virus type 1-infected individual with low viral load harbors a virus variant that exhibits an in vitro RNA dimerization defect. J Virol (2004) 0.86
Innate and adaptive factors regulating human immunodeficiency virus type 1 genomic activation. J Neuroimmune Pharmacol (2010) 0.85
Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I. Virol J (2014) 0.80
In search of a function for the most frequent naturally-occurring length polymorphism (MFNLP) of the HIV-1 LTR: retaining functional coupling, of Nef and RBF-2, at RBEIII? Int J Biol Sci (2007) 0.80
Impact of viral activators and epigenetic regulators on HIV-1 LTRs containing naturally occurring single nucleotide polymorphisms. Biomed Res Int (2015) 0.77
Human Immunodeficiency Virus (HIV). Transfus Med Hemother (2016) 0.75
A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. AIDS Clinical Trials Group Study 175 Study Team. N Engl J Med (1996) 7.60
Nucleotide sequence heterogeneity of an RNA phage population. Cell (1978) 5.55
Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. AIDS (1999) 4.39
Rapid fitness losses in mammalian RNA virus clones due to Muller's ratchet. Proc Natl Acad Sci U S A (1992) 4.22
Impact of protein kinase PKR in cell biology: from antiviral to antiproliferative action. Microbiol Mol Biol Rev (2006) 4.13
A potential role for interleukin-7 in T-cell homeostasis. Blood (2001) 3.56
The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance--a review. Gene (1985) 3.42
Membrane raft microdomains mediate lateral assemblies required for HIV-1 infection. EMBO Rep (2000) 3.23
Mutation frequencies at defined single codon sites in vesicular stomatitis virus and poliovirus can be increased only slightly by chemical mutagenesis. J Virol (1990) 3.11
Multiple genetic variants arise in the course of replication of foot-and-mouth disease virus in cell culture. Virology (1983) 3.04
Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. J Viral Hepat (2009) 3.02
The proportion of revertant and mutant phage in a growing population, as a function of mutation and growth rate. Gene (1976) 2.77
Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol (1995) 2.68
Exponential increases of RNA virus fitness during large population transmissions. Proc Natl Acad Sci U S A (1995) 2.60
Genetic bottlenecks and population passages cause profound fitness differences in RNA viruses. J Virol (1993) 2.55
Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS (2001) 2.47
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Nucleotide sequence heterogeneity of the RNA from a natural population of foot-and-mouth-disease virus. Gene (1980) 2.44
Genetic lesions associated with Muller's ratchet in an RNA virus. J Mol Biol (1996) 2.41
Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr (1999) 2.36
Lack of evolutionary stasis during alternating replication of an arbovirus in insect and mammalian cells. J Mol Biol (1999) 2.28
Virus mutation frequencies can be greatly underestimated by monoclonal antibody neutralization of virions. J Virol (1989) 2.27
Response of foot-and-mouth disease virus to increased mutagenesis: influence of viral load and fitness in loss of infectivity. J Virol (2000) 2.26
Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene (1992) 2.20
A dominant negative protein kinase C zeta subspecies blocks NF-kappa B activation. Mol Cell Biol (1993) 2.20
Size of genetic bottlenecks leading to virus fitness loss is determined by mean initial population fitness. J Virol (1995) 2.18
Evolution of cell recognition by viruses. Science (2001) 2.14
Subclonal components of consensus fitness in an RNA virus clone. J Virol (1994) 2.09
RNA virus quasispecies: significance for viral disease and epidemiology. Infect Agents Dis (1994) 2.08
KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene (2006) 2.07
The two species of the foot-and-mouth disease virus leader protein, expressed individually, exhibit the same activities. Virology (1993) 2.05
Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med (1983) 2.01
The state of hepatitis B and C in Europe: report from the hepatitis B and C summit conference*. J Viral Hepat (2011) 2.00
Multiple molecular pathways for fitness recovery of an RNA virus debilitated by operation of Muller's ratchet. J Mol Biol (1999) 2.00
[Treatment and prophylaxis of the principal infections associated with the human immunodeficiency virus]. Med Clin (Barc) (1993) 1.96
Genetic variability of Hong Kong (H3N2) influenza viruses: spontaneous mutations and their location in the viral genome. Gene (1980) 1.95
Rapid selection of genetic and antigenic variants of foot-and-mouth disease virus during persistence in cattle. J Virol (1988) 1.92
Coevolution of cells and viruses in a persistent infection of foot-and-mouth disease virus in cell culture. J Virol (1988) 1.90
Fitness alteration of foot-and-mouth disease virus mutants: measurement of adaptability of viral quasispecies. J Virol (1991) 1.89
Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol (2001) 1.86
Drastic fitness loss in human immunodeficiency virus type 1 upon serial bottleneck events. J Virol (1999) 1.85
Establishment of cell lines persistently infected with foot-and-mouth disease virus. Virology (1985) 1.84
European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. HIV Med (2008) 1.84
Extreme fitness differences in mammalian and insect hosts after continuous replication of vesicular stomatitis virus in sandfly cells. J Virol (1995) 1.84
The red queen reigns in the kingdom of RNA viruses. Proc Natl Acad Sci U S A (1994) 1.83
Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol (2001) 1.83
Clonality assessment and clonal ordering of individual neoplastic crypts shows polyclonality of colorectal adenomas. Gastroenterology (2010) 1.83
The structure and antigenicity of a type C foot-and-mouth disease virus. Structure (1994) 1.82
Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: report of five cases and review. Clin Infect Dis (1994) 1.82
RNA virus evolution and the control of viral disease. Prog Drug Res (1989) 1.74
Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. European Concerted Action on Viral Hepatitis (EUROHEP) Am J Gastroenterol (1998) 1.74
In vitro site-directed mutagenesis: generation and properties of an infectious extracistronic mutant of bacteriophage Qbeta. Gene (1976) 1.72
Evolution of the capsid protein genes of foot-and-mouth disease virus: antigenic variation without accumulation of amino acid substitutions over six decades. J Virol (1992) 1.72
Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. Proc Natl Acad Sci U S A (1989) 1.71
Memory in viral quasispecies. J Virol (2000) 1.70
Recovery of the immune system with antiretroviral therapy: the end of opportunism? JAMA (1998) 1.68
Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev (1997) 1.65
Evolution of the nucleotide sequence of influenza virus RNA segment 7 during drift of the H3N2 subtype. Gene (1983) 1.64
Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin Infect Dis (2012) 1.62
Molecular indetermination in the transition to error catastrophe: systematic elimination of lymphocytic choriomeningitis virus through mutagenesis does not correlate linearly with large increases in mutant spectrum complexity. Proc Natl Acad Sci U S A (2002) 1.60
Exponential fitness gains of RNA virus populations are limited by bottleneck effects. J Virol (1999) 1.60
Introduction of HIV drug-resistance testing in clinical practice. AIDS (1999) 1.58
A single amino acid substitution affects multiple overlapping epitopes in the major antigenic site of foot-and-mouth disease virus of serotype C. J Gen Virol (1990) 1.57
Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. AIDS (2001) 1.56
Origin and evolution of viruses. Virus Genes (1998) 1.56
Markers of inflammation and CD8 T-cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in HIV-infected individuals. HIV Med (2013) 1.56
Risk of acute liver injury associated with the use of drugs: a multicentre population survey. Aliment Pharmacol Ther (2007) 1.55
Induction of apoptosis by double-stranded-RNA-dependent protein kinase (PKR) involves the alpha subunit of eukaryotic translation initiation factor 2 and NF-kappaB. Mol Cell Biol (1999) 1.54
Fixation of mutations in the viral genome during an outbreak of foot-and-mouth disease: heterogeneity and rate variations. Gene (1986) 1.53
Multiple virulence determinants of foot-and-mouth disease virus in cell culture. J Virol (1998) 1.52
Foot-and-mouth disease virus lacking the VP1 G-H loop: the mutant spectrum uncovers interactions among antigenic sites for fitness gain. Virology (2001) 1.50
A single nucleotide substitution in the internal ribosome entry site of foot-and-mouth disease virus leads to enhanced cap-independent translation in vivo. J Virol (1993) 1.50
Invasive infection with Saccharomyces cerevisiae: report of three cases and review. Rev Infect Dis (1990) 1.49
Etiology and microbial patterns of pulmonary infiltrates in patients with orthotopic liver transplantation. Chest (2000) 1.49
Endoscopic sclerotherapy in upper gastrointestinal bleeding due to the Mallory-Weiss syndrome. Am J Gastroenterol (1994) 1.48
Component-resolved diagnosis of vespid venom-allergic individuals: phospholipases and antigen 5s are necessary to identify Vespula or Polistes sensitization. Allergy (2012) 1.48
Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995--1999. Clin Infect Dis (2000) 1.47
Increases in T cell telomere length in HIV infection after antiretroviral combination therapy for HIV-1 infection implicate distinct population dynamics in CD4+ and CD8+ T cells. Clin Immunol (1999) 1.47
Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol (1997) 1.47
The proportion of tumor-stroma as a strong prognosticator for stage II and III colon cancer patients: validation in the VICTOR trial. Ann Oncol (2012) 1.46
Negative effects of chemical mutagenesis on the adaptive behavior of vesicular stomatitis virus. J Virol (1997) 1.45
Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Methods (2005) 1.45
[Strongyloidiasis and HTLV-I infection]. Med Clin (Barc) (1999) 1.44
Human immunodeficiency virus type 1 reverse transcriptase: role of Tyr115 in deoxynucleotide binding and misinsertion fidelity of DNA synthesis. EMBO J (1996) 1.44
Thymic size and lymphocyte restoration in patients with human immunodeficiency virus infection after 48 weeks of zidovudine, lamivudine, and ritonavir therapy. J Infect Dis (2000) 1.43
Extensive antigenic heterogeneity of foot-and-mouth disease virus of serotype C. Virology (1988) 1.42
[Interferon in chronic hepatitis in patients infected by the human immunodeficiency virus: yes or no?]. Med Clin (Barc) (1992) 1.40
Modifications of the 5' untranslated region of foot-and-mouth disease virus after prolonged persistence in cell culture. Virus Res (1992) 1.40
Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.40
[The usefulness of Doppler echocardiography in the preoperative assessment of valvulopathies. A comparison with the hemodynamic and surgical findings]. Rev Esp Cardiol (1993) 1.40
Many-trillionfold amplification of single RNA virus particles fails to overcome the Muller's ratchet effect. J Virol (1993) 1.40
Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. EMBO J (2000) 1.40
[An esophageal ulcer due to cytomegalovirus in a female patient infected with the human immunodeficiency virus without serious immunosuppression: is this an acquired immunodeficiency syndrome?]. Med Clin (Barc) (1992) 1.40
[Complications in Mediterranean boutonneuse fever: prospective study of 78 patients]. Rev Clin Esp (1989) 1.39
[Predictive factors of mortality in a series of 61 patients with severe acute pancreatitis]. Med Clin (Barc) (1990) 1.39
[Intensification of antiretroviral treatment]. Rev Clin Esp (2000) 1.39
[Antiretroviral treatment against HIV]. Med Clin (Barc) (1995) 1.39
HTLV-I and HTLV-II infections in Spain. Vox Sang (1993) 1.39